Edgars Celms

Edgars Celms

Auto-generated profile, based on publicly available information

Edgars Celms

University of Latvia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGhislaine Scelo
Ghislaine Scelo
YRYasser Riazalhosseini
Yasser Riazalhosseini
LGLiliana Greger
Liliana Greger
LLLouis Letourneau
Louis Letourneau
MGMar Gonzàlez-Porta
Mar Gonzàlez-Porta
GLG. Mark Lathrop
G. Mark Lathrop
The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and genes encoding FAT cadherins. Furthermore, a large majority of patients from Romania have an unexpected high frequency of A:T>T:A transversions, consistent with exposure to aristolochic acid (AA). These results show that the processes underlying ccRCC tumorigenesis may vary in different populations and suggest that AA may be an important ccRCC carcinogen in Romania, a finding with major public health implications.

1 January 2005 in Lecture Notes in Computer Science
Verified
Book Chapter
Closed access
PDF file
AKAudris Kalnins
Audris Kalnins
JBJanis Barzdins
Janis Barzdins
ECEdgars Celms
Edgars Celms

1 March 2020 in Parallel Computing
Verified
Journal Article
Closed access
VAVasco Amaral
Vasco Amaral
BNBeatriz Norberto
Beatriz Norberto
MGMiguel Goulão
Miguel Goulão
MAMarco Aldinucci
Marco Aldinucci
SBSiegfried Benkner
Siegfried Benkner
AVAri Visa
Ari Visa

9 February 2007 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
JVJuris Vīksna
Juris Vīksna
ECEdgars Celms
Edgars Celms
MOMartins Opmanis
Martins Opmanis
KPKarlis Podnieks
Karlis Podnieks
PRPeteris Rucevskis
Peteris Rucevskis
USUgis Sarkans
Ugis Sarkans
Background: One of the crucial aspects of day-to-day laboratory information management is collection, storage and retrieval of information about research subjects and biomedical samples. An efficient link between sample data and experiment results is absolutely imperative for a successful outcome of a biomedical study. Currently available software solutions are largely limited to large-scale, expensive commercial Laboratory Information Management Systems (LIMS). Acquiring such LIMS indeed can bring laboratory information management to a higher level, but often implies sufficient investment of time, effort and funds, which are not always available. There is a clear need for lightweight open source systems for patient and sample information management. Results: We present a web-based tool for submission, management and retrieval of sample and research subject data. The system secures confidentiality by separating anonymized sample information from individuals' records. It is simple and generic, and can be customised for various biomedical studies. Information can be both entered and accessed using the same web interface. User groups and their privileges can be defined. The system is open-source and is supplied with an on-line tutorial and necessary documentation. It has proven to be successful in a large international collaborative project. Conclusion: The presented system closes the gap between the need and the availability of lightweight software solutions for managing information in biomedical studies involving human research subjects.

23 February 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NVNaveen S. Vasudev
Naveen S. Vasudev
GSGhislaine Scelo
Ghislaine Scelo
KGKate I. Glennon
Kate I. Glennon
MWMichelle Wilson
Michelle Wilson
LLLouis Letourneau
Louis Letourneau
RBRosamonde Banks
Rosamonde Banks
Purpose: Patients with resected localized clear-cell renal cell carcinoma (ccRCC) remain at variable risk of recurrence. Incorporation of biomarkers may refine risk prediction and inform adjuvant treatment decisions. We explored the role of tumor genomics in this setting, leveraging the largest cohort to date of localized ccRCC tissues subjected to targeted gene sequencing. Experimental Design: The somatic mutation status of 12 genes was determined in 943 ccRCC cases from a multinational cohort of patients, and associations to outcomes were examined in a Discovery (n = 469) and Validation (n = 474) framework. Results: Tumors containing a von-Hippel Lindau (VHL) mutation alone were associated with significantly improved outcomes in comparison with tumors containing a VHL plus additional mutations. Within the Discovery cohort, those with VHL+0, VHL+1, VHL+2, and VHL+≥3 tumors had disease-free survival (DFS) rates of 90.8%, 80.1%, 68.2%, and 50.7% respectively, at 5 years. This trend was replicated in the Validation cohort. Notably, these genomically defined groups were independent of tumor mutational burden. Amongst patients eligible for adjuvant therapy, those with a VHL+0 tumor (29%) had a 5-year DFS rate of 79.3% and could, therefore, potentially be spared further treatment. Conversely, patients with VHL+2 and VHL+≥3 tumors (32%) had equivalent DFS rates of 45.6% and 35.3%, respectively, and should be prioritized for adjuvant therapy. Conclusions: Genomic characterization of ccRCC identified biologically distinct groups of patients with divergent relapse rates. These groups account for the ∼80% of cases with VHL mutations and could be used to personalize adjuvant treatment discussions with patients as well as inform future adjuvant trial design.

16 September 2020 in Proteomics
Verified
Journal Article
Open access
PDF file
MBMitra Parissa Barzine
Mitra Parissa Barzine
KFKarlis Freivalds
Karlis Freivalds
JWJames C. Wright
James C. Wright
MOMārtiņš Opmanis
Mārtiņš Opmanis
DRDarta Rituma
Darta Rituma
JVJuris Vīksna
Juris Vīksna
Motivation Mass spectrometry (MS) based quantitative proteomics experiments typically assay a subset of up to 60% of the ∼20,000 human protein coding genes. Computational methods for imputing the missing values using RNA expression data usually allow only for imputations of proteins measured in at least some of the samples. In silico methods for comprehensively estimating abundances across all proteins are still missing. Results We propose a novel method using deep learning to extrapolate the observed protein expression values in label‐free MS experiments to all proteins, leveraging gene functional annotations and RNA measurements as key predictive attributes. We tested our method on four datasets, including human cell lines and human and mouse tissues. Our method predicts the protein expression values with average R2scores between 0.46 and 0.54, which is significantly better than predictions based on correlations using the RNA expression data alone. Moreover, we demonstrate that the derived models can be “transferred” across experiments and species. For instance, the model derived from human tissues gave a R2 = 0.51 when applied to mouse tissue data. We conclude that protein abundances generated in label free MS experiments can be computationally predicted using functional annotated attributes and can be used to highlight aberrant protein abundance values. This article is protected by copyright. All rights reserved